Isofol Medical AB (SE:ISOFOL)
:ISOFOL
ISOFOL Stock Chart & Stats
kr0.72
-kr0.10(-6.34%)
At close: 4:00 PM EST
kr0.72
-kr0.10(-6.34%)
Day’s Range― - ―
52-Week Rangekr0.55 - kr2.02
Previous CloseN/A
Volume134.77K
Average Volume (3M)501.89K
Market Cap
kr182.72M
Enterprise Valuekr140.73M
Total Cash (Recent Filing)kr126.99M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.57
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding281,107,240
10 Day Avg. Volume847,726
30 Day Avg. Volume501,890
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / No DebtIsofol's lack of recorded debt across 2023–2025 materially reduces fixed financial obligations, lowering bankruptcy and interest-rate risk. For a pre-commercial biotech this preserves strategic flexibility to pursue R&D or partnerships and reduces near-term cash drain from debt servicing.
Reduced Cash Burn Vs Earlier YearsOperating cash outflows have declined meaningfully from the -160M to -191M range seen in 2020–2022 to roughly -51.9M in 2025, reflecting tighter cost control and greater cash efficiency. This durable reduction extends runway and lowers the scale of future financing needs absent revenue.
Focused R&D Business ModelA clear, narrow scientific focus on adjunctive cancer therapies concentrates resources and expertise, enabling efficient trial design and partner interest. As a pre-commercial R&D company with a small team, this specialization supports disciplined capital deployment and potential high-margin product upside if clinical success follows.
Bears Say
No Revenue (pre-commercial)Isofol reported no revenues in 2024–2025, leaving the company reliant entirely on external capital rather than product cash flows. Over a 2–6 month horizon this structural lack of operating income constrains reinvestment capacity and elevates execution risk for advancing clinical programs without dilution.
Persistent And Worsening Net LossesLarge, growing net losses (≈-54.2M in 2025) indicate the company's R&D and operating costs outpace resources. Over time this erodes equity and investor cushion, reduces financial resilience, and increases the probability of further equity raises that dilute existing holders and constrain long-term strategic options.
Negative Operating Cash Flow And Funding DependenceSustained negative operating cash flow and negative free cash flow create a structural need for external financing to sustain operations. Even with improved burn versus earlier years, ongoing cash consumption limits autonomy, risks timing mismatches with financing markets, and may force dilutive or restrictive funding terms.
Isofol Medical AB News
ISOFOL FAQ
What was Isofol Medical AB’s price range in the past 12 months?
Isofol Medical AB lowest stock price was kr0.55 and its highest was kr2.02 in the past 12 months.
What is Isofol Medical AB’s market cap?
Isofol Medical AB’s market cap is kr182.72M.
When is Isofol Medical AB’s upcoming earnings report date?
Isofol Medical AB’s upcoming earnings report date is May 19, 2026 which is in 39 days.
How were Isofol Medical AB’s earnings last quarter?
Isofol Medical AB released its earnings results on Feb 18, 2026. The company reported -kr0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.05.
Is Isofol Medical AB overvalued?
According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued.
Does Isofol Medical AB pay dividends?
Isofol Medical AB does not currently pay dividends.
What is Isofol Medical AB’s EPS estimate?
Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Isofol Medical AB have?
Isofol Medical AB has 281,107,240 shares outstanding.
What happened to Isofol Medical AB’s price movement after its last earnings report?
Isofol Medical AB reported an EPS of -kr0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.13%.
Which hedge fund is a major shareholder of Isofol Medical AB?
Currently, no hedge funds are holding shares in SE:ISOFOL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Isofol Medical AB
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.
Technical Analysis
Xintela AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Bio-Works Technologies AB
―